TICKERNERD
Menu
CNTBCNTBHealthcare · Biotechnology

CNTB Stock Forecast: Connect Biopharma Holdings Ltd. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$2.04
−0.97% on the day

The 8 Wall Street analysts covering Connect Biopharma Holdings Ltd. hold a median 12-month price target of $7 — +243.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$128.5M
Ticker Nerd rank
25 / 100
Median analyst target
$7.00
Analysts covering
8
Revenue$2.8M+5666.7% y/y
Operating income−$17.6M
Net income−$17.3M
Free cash flow−$15.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+5.7%
1M
−8.9%
YTD
−27.7%
1Y
+25.2%
From 52W high
−44.7%
From 52W low
+54.9%
$1.32
$3.69
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CNTB stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Connect Biopharma Holdings Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
25 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
79
Size
73
Revisions
59
Issuance
39
Value
32
Volatility
32
Growth
23
Momentum
8
Quality
8

Accruals (79): Reported profit is backed by cash, and the company is not expanding recklessly.

Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CNTB stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNTB, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Oct 25Jan 26Apr 26Jul 26CNTBHigh $10.00Median $7.00Low $4.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $4.00Median $7.00High $10.00

The green dot is the last close — the median target sits +243.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 July 2026OppenheimerInitiatesOutperform$8.00
9 July 2026OppenheimerInitiatesOutperform—
26 June 2026Piper SandlerInitiatesOverweight—
25 June 2026HC Wainwright & Co.ReiteratesBuy—
26 May 2026Canaccord GenuityInitiatesBuy—
21 May 2026Cantor FitzgeraldInitiatesOverweight—
1 Apr 2026BTIGReiteratesBuy—
31 Mar 2026BTIGReiteratesBuy—
1 Dec 2025Lake StreetInitiatesBuy—
13 Nov 2025BTIGReiteratesBuy—
31 Oct 2025BTIGInitiatesBuy—
13 Aug 2025HC Wainwright & Co.ReiteratesBuy—
12 June 2025HC Wainwright & Co.AssumesBuy$7.00
1 Apr 2025HC Wainwright & Co.ReiteratesBuy—
31 Mar 2025HC Wainwright & Co.ReiteratesBuy—
6 Sept 2024HC Wainwright & Co.ReiteratesBuy—
13 June 2024HC Wainwright & Co.ReiteratesBuy—
17 Apr 2024HC Wainwright & Co.MaintainsBuy—
4 Mar 2024HC Wainwright & Co.InitiatesBuy—
13 Sept 2023Cantor FitzgeraldReiteratesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CNTB appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

CNTB vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Connect Biopharma Holdings Ltd. returned +25.2% against +17.5% for the S&P 500, dividends included.

CNTB vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Oct 25Jan 26Apr 26Jul 26CNTBS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CNTB analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
4
Analysts cutting
0
Fundamentals

Connect Biopharma Holdings Ltd. (CNTB) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.0×

Cheaper than 85% of US stocks

Price / sales
43.5×

Cheaper than 6% of US stocks

Price / book
4.8×

Cheaper than 21% of US stocks

EV / EBITDA
−1.4×

Cheaper than 69% of US stocks

Growth & margins
Revenue growth (YoY)
5666.7%

Higher than 99% of US stocks

Earnings growth (YoY)
5666.7%

Higher than 99% of US stocks

Gross margin
—
Operating margin
−636.0%

Higher than 7% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−140.5%

Higher than 10% of US stocks

Return on assets
−69.7%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Connect Biopharma Holdings Ltd. (CNTB) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Connect Biopharma Holdings Ltd. has a market value of $128.5M and an enterprise value of $97.6M.

  • Revenue in the twelve months to 30 June 2026: $3.0M. The latest quarter grew 5666.7% year on year.

  • Net income over the same four quarters: −$69.0M, a −2336.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.19.

  • Free cash flow in the twelve months to 30 June 2026: −$60.6M.

  • Shares outstanding: 63.0M.

  • Trailing P/E: −2.0×; forward P/E: −2.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Connect Biopharma Holdings Ltd. employs 64 people — $46K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

CNTB vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CNTBConnect Biopharma Holdings Ltd.$128.5M
25
INOInovio Pharmaceuticals, Inc.$129.2M
42
NAUTNautilus Biotechnology, Inc.$129.6M
52
VTVTvTv Therapeutics, Inc.$125.9M
77
OKUROnKure Therapeutics, Inc.$125.2M
52
HURATuHURA Biosciences, Inc.$124.5M
19
EQEquillium, Inc.$133.4M
43

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Connect Biopharma Holdings Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CNTB news & analysis

Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 3 Sept 2026neutral

Connect Biopharma announced that company management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The company, a clinical-stage biopharmaceutical firm focused on inflammatory disease treatments, will be represented at the event.

Why it matters — CNTB watchers might be interested as this provides an opportunity for the company's management to present its work to the investment community.

Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update

GlobeNewsWire · 12 Aug 2026positive

Connect Biopharma reported financial results for the three and six months ended June 30, 2026, and provided a business update. The company completed enrollment in both Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD, expects to report topline results in September 2026, and stated its cash runway is expected to last at least one year from the release date.

Why it matters — The completion of enrollment in both Phase 2 studies brings CNTB closer to key topline data in September 2026, while the confirmed cash runway supports ongoing operations for at least another year.

FAQ

Frequently asked questions about CNTB stock

What is the CNTB stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Connect Biopharma Holdings Ltd. have a median 12-month price target of $7, with estimates ranging from $4 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CNTB stock a buy right now?

Of the 8 analysts covering Connect Biopharma Holdings Ltd., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Connect Biopharma Holdings Ltd. 25 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CNTB?

As at 12 Sept 2026, Connect Biopharma Holdings Ltd. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (79 of 100).

Will CNTB stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +243.1% from the last close, and Ticker Nerd's factor model ranks Connect Biopharma Holdings Ltd. 25 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CNTB stock forecast for 2030?

No analyst covering Connect Biopharma Holdings Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNTB are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $10 over the next 12 months.

How has CNTB stock performed over the past year?

Connect Biopharma Holdings Ltd. returned +25.2% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Connect Biopharma Holdings Ltd. do?

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. The company concentrates on immune-mediated conditions, with its lead programs centered on antibodies designed to target pathways involved in asthma and chronic obstructive pulmonary disease.

What is the latest news on CNTB?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference". Connect Biopharma announced that company management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The company, a clinical-stage biopharmaceutical firm focused on inflammatory disease treatments, will be represented at the event.

Company

About Connect Biopharma Holdings Ltd.

Connect Biopharma Holdings Limited is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases. The company concentrates on immune-mediated conditions, with its lead programs centered on antibodies designed to target pathways involved in asthma and chronic obstructive pulmonary disease. Its current pipeline is built around rademikibart, a monoclonal antibody aimed at interleukin-4 receptor alpha, as well as other research efforts in T cell-driven inflammatory disorders. Connect Biopharma works across respiratory and broader inflammation-related markets, reflecting a focus on diseases where immune signaling plays a central role. Headquartered in San Diego, California, Connect Biopharma Holdings Limited is positioned as a specialist developer of novel biologic treatments within the biotechnology sector.

CEO Dr. Barry David Quart Pharm.D. · 64 employees · United States · https://www.connectbiopharm.com